Sihuan Pharmaceutical Holdings Group (SEHK:460) - Aktienkurs, Nachrichten und Analyse

460 Aktienübersicht

Die Sihuan Pharmaceutical Holdings Group Ltd. ist eine Investment-Holdinggesellschaft, die in der Volksrepublik China in den Bereichen Forschung und Entwicklung, Herstellung, Marketing und Verkauf von pharmazeutischen und medizinisch-ästhetischen Produkten tätig ist.

Über das Unternehmen

460 grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	0/6
Künftiges Wachstum	0/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	3/6
Dividenden	2/6

Belohnungen

Die Erträge sind in den letzten 5 Jahren um 13% pro Jahr gestiegen.

Risikoanalyse

Die Dividende von 7.74% ist nicht gut durch Erträge oder freie Cashflows gedeckt

Sihuan Pharmaceutical Holdings Group Ltd. Wettbewerber

Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd

SEHK:1349

HK$7.5b

Beijing Tong Ren Tang Chinese Medicine

SEHK:3613

HK$8.0b

Consun Pharmaceutical Group

SEHK:1681

HK$6.4b

China Shineway Pharmaceutical Group

SEHK:2877

HK$7.2b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Sihuan Pharmaceutical Holdings Group
Historische Aktienkurse
Aktueller Aktienkurs	HK$0.72
52-Wochen-Hoch	HK$0.72
52-Wochen-Tief	HK$0.49
Beta	0.60
11 Monat Veränderung	30.91%
3 Monate Veränderung	35.85%
1 Jahr Veränderung	20.00%
33 Jahre Veränderung	-54.14%
5 Jahre Veränderung	-36.28%
Veränderung seit IPO	-75.04%

Aktuelle Nachrichten und Updates

What Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 25% Share Price Gain Is Not Telling You

Oct 02

Is Sihuan Pharmaceutical Holdings Group (HKG:460) Using Too Much Debt?

Sep 30

Recent updates

What Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 25% Share Price Gain Is Not Telling You

Oct 02

Is Sihuan Pharmaceutical Holdings Group (HKG:460) Using Too Much Debt?

Sep 30

Here's Why It's Unlikely That Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) CEO Will See A Pay Rise This Year

May 31

Investors Still Waiting For A Pull Back In Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

May 27

A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Dec 05

Health Check: How Prudently Does Sihuan Pharmaceutical Holdings Group (HKG:460) Use Debt?

Oct 31

Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Aug 19

Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Apr 21

Is Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Worth HK$0.8 Based On Its Intrinsic Value?

Nov 03

Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?

Oct 11

Is There An Opportunity With Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 34% Undervaluation?

Jun 21

Estimating The Intrinsic Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Mar 09

A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Nov 28

Sihuan Pharmaceutical Holdings Group (HKG:460) Seems To Use Debt Rather Sparingly

Sep 26

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) CEO For Now

Jun 22

How Does Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Fare As A Dividend Stock?

May 11

Sihuan Pharmaceutical Holdings Group's (HKG:460) Shareholders May Want To Dig Deeper Than Statutory Profit

Mar 30

How Much Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Do Insiders Own?

Mar 07

Should You Buy Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) For Its Dividend?

Feb 07

Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Jan 11

Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?

Dec 21

Why Sihuan Pharmaceutical Holdings Group's (HKG:460) CEO Pay Matters

Dec 07

Aktionärsrenditen

	460	HK Pharmaceuticals	HK Markt
7D	24.1%	10.3%	9.6%
1Y	20.0%	34.6%	27.2%

Rendite im Vergleich zur Industrie: 460 unter dem Niveau der Branche Hong Kong Pharmaceuticals , die im vergangenen Jahr eine Rendite von -6.5% erzielte.

Rendite vs. Markt: 460 hinter dem Markt Hong Kong zurück, der im vergangenen Jahr eine Rendite von 19.7 erzielte.

Preisvolatilität

Is 460's price volatile compared to industry and market?
460 volatility
460 Average Weekly Movement	6.0%
Pharmaceuticals Industry Average Movement	5.5%
Market Average Movement	7.9%
10% most volatile stocks in HK Market	17.4%
10% least volatile stocks in HK Market	3.8%

Stabiler Aktienkurs: 460 hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: 460Die wöchentliche Volatilität (7%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2001	2,648	Weicheng Guo	www.sihuanpharm.com

Die Sihuan Pharmaceutical Holdings Group Ltd. ist eine Investmentholding, die in der Volksrepublik China in den Bereichen Forschung und Entwicklung, Herstellung, Marketing und Verkauf von pharmazeutischen und medizinisch-ästhetischen Produkten tätig ist. Das Unternehmen ist in drei Segmenten tätig: Medizinisch-ästhetische Produkte, Innovative Medizin und andere Medizin sowie Generika.

Sihuan Pharmaceutical Holdings Group Ltd.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Sihuan Pharmaceutical Holdings Group im Vergleich zum Marktanteil des Unternehmens?
460 grundlegende Statistiken
Marktanteil	HK$6.71b
Gewinn(TTM)	-HK$41.61m
Umsatz(TTM)	HK$1.93b

3.5x

Kurs-Umsatz-Verhältnis

-161.3x

Kurs-Gewinn-Verhältnis

Ist 460 zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
460 Gewinn- und Verlustrechnung (TTM)
Einnahmen	CN¥1.75b
Kosten der Einnahmen	CN¥598.10m
Bruttogewinn	CN¥1.16b
Sonstige Ausgaben	CN¥1.19b
Umsatz	-CN¥37.80m

Zuletzt gemeldete Gewinne

Jun 30, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-0.0041
Bruttomarge	65.91%
Nettogewinnspanne	-2.15%
Schulden/Eigenkapital-Verhältnis	21.4%

Wie hat sich 460 auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

5.8%

Aktuelle Dividendenrendite

-467%

Ausschüttungsquote

460 Aktienübersicht

Belohnungen

Risikoanalyse

Sihuan Pharmaceutical Holdings Group Ltd. Wettbewerber

SEHK:1349

HK$7.5b

SEHK:3613

HK$8.0b

SEHK:1681

HK$6.4b

SEHK:2877

HK$7.2b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

What Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 25% Share Price Gain Is Not Telling You

Is Sihuan Pharmaceutical Holdings Group (HKG:460) Using Too Much Debt?

Upcoming dividend of HK$0.021 per share

First half 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.005 loss in 1H 2023)

Sihuan Pharmaceutical Holdings Group Ltd. Announces Interim Ordinary Cash Dividend for the Six Months Ended June 30, 2024, Payable on 10 October 2024

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Recent updates

What Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 25% Share Price Gain Is Not Telling You

Is Sihuan Pharmaceutical Holdings Group (HKG:460) Using Too Much Debt?

Upcoming dividend of HK$0.021 per share

First half 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.005 loss in 1H 2023)

Sihuan Pharmaceutical Holdings Group Ltd. Announces Interim Ordinary Cash Dividend for the Six Months Ended June 30, 2024, Payable on 10 October 2024

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Sihuan Pharmaceutical Holdings Group Ltd.'s Honghe Pharmaceutical Co., Ltd. Obtains Drug Registration Approval from National Medical Products Administration

New major risk - Revenue and earnings growth

Sihuan Pharmaceutical Holdings Group Ltd. Announces Rivaroxaban Tablets (Strength: 2.5Mg) Obtained Drug Registration Approval from NMPA

Here's Why It's Unlikely That Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) CEO Will See A Pay Rise This Year

Investors Still Waiting For A Pull Back In Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Now 21% undervalued after recent price drop

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, Jun 07, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Sihuan Pharmaceutical Holdings Group Ltd. Receives Registration Approval from National Medical Products Administration for Proline Janagliflozin Tablets

Now 20% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration of the People's Republic of China for the Treatment of Diabetes

A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Health Check: How Prudently Does Sihuan Pharmaceutical Holdings Group (HKG:460) Use Debt?

National Medical Products Administration Approves IND Application of Insulin Degludec and Liraglutide Injection, Developed by Huisheng Biopharmaceutical

First half 2023 earnings released: CN¥0.005 loss per share (vs CN¥0.004 profit in 1H 2022)

Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2023 Results on Aug 29, 2023

Sihuan Pharmaceutical Holdings Group Ltd. Announces Huisheng Biopharmaceutical's Drug Semaglutide Injection Obtained Approval for Clinical Trial

Sihuan Pharmaceutical Holdings Group Ltd. Announces Approval of Phase II Clinical Trial Application of Birociclib by the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China

Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration

Upcoming dividend of HK$0.037 per share at 9.7% yield

Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Full year 2022 earnings released: CN¥0.21 loss per share (vs CN¥0.044 profit in FY 2021)

Sihuan Pharmaceutical Holdings Group Ltd. Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Less than half of directors are independent

Is Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Worth HK$0.8 Based On Its Intrinsic Value?

Sihuan Pharmaceutical Holdings Group Ltd. Announces Management Changes

Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?

Upcoming dividend of HK$0.037 per share

Sihuan Pharmaceutical Holdings Group Ltd. Declares Special Cash Dividend for the Six Months Ended 30 June 2022, Payable on or Around 13 October 2022

First half 2022 earnings released: EPS: CN¥0.004 (vs CN¥0.065 in 1H 2021)

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2022 Results on Aug 30, 2022

Sihuan Pharmaceutical Holdings Group Ltd. Provides Earnings Guidance for the Six Months Ended 30 June 2022

Sihuan Pharmaceutical Holdings Group Ltd. Announces Acceptance of Application for Marketing of Xuanzhu Biopharm\U0027s Drug Fulvestrant Injection by Nmpa of China

Is There An Opportunity With Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 34% Undervaluation?

Upcoming dividend of HK$0.13 per share

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Sihuan Pharmaceutical Obtains Class III Medical Device Registration Certificate from NMPA for Exclusively Distributed Hyaluronic Acid Persnica

Now 20% undervalued

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, May 24, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

Sihuan Pharmaceutical Holdings Group Ltd. Announces Ordinary Final Cash Dividend for the Year Ended December 31, 2021, Payable on June 14, 2022

Investor sentiment deteriorated over the past week

Now 25% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Announces First Class I Macromolecule Innovative Drug Her2 Bispecific Antibody Xzp-Km257 Was Approves for Clinical Trails

Estimating The Intrinsic Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Investor sentiment improved over the past week

National Medical Products Administration Accepts Biologics License Application of Insulin Aspart Injection, Insulin Aspart 30 Injection and Insulin Aspart 50 Injection of Jilin Huisheng Biopharmaceutical Co., Ltd

Now 22% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Announces Medical Device Registration Certificate Obtained for Medical Skin Care Gel and Repair Gel

Sihuan Pharmaceutical Holdings Group Ltd. Announces Fondaparinux Sodium Injection Obtained Manufacture Approval

Erträge & Einnahmen